|
| Maintaining higher dose at follow-up visit |
| Dose escalation at follow-up visit |
| ||
|
| Fesoterodine 156 | Solifenacin 48 | p value | Fesoterodine 194 | Solifenacin 134 | p value |
| Concomitant treatment, mean (SD) | 2.4 (1.8) | 2.5 (1.8) | NS | 2.1 (1.3) | 2.4 (1.4) | NS |
| Concomitant treatment, n (%) | 118 (75.6) | 32 (66.7) | NS | 149 (76.8) | 100 (74.6) | NS |
| NASID | 43 (36.4) | 14 (43.8) | NS | 51 (34.2) | 42 (42.0) | NS |
| ACE inhibitors | 25 (21.2) | 6 (18.8) | NS | 29 (19.5) | 26 (26.0) | NS |
| *Uroselectivealpha1-blocker | 6/21 (28.5) | 2/8 (25.0) | NS | 23/50 (46.0) | 9/36 (25.0) | 0.047 |
| Antibiotics for UTI | 16 (13.6) | 5 (15.6) | NS | 26 (17.4) | 9 (9.0) | NS |
| Hypnotics | 16 (13.6) | 6 (18.8) | NS | 19 (12.8) | 17 (17.0) | NS |
| SSRIs | 13 (11.0) | 7 (21.9) | NS | 19 (12.8) | 13 (13.0) | NS |